Giles Roditi1, Tara Collidge2, Peter Thomson2, Keith Simpson2, Scott Morris2, Brown Michaela2, Anirudh Rao2
1Radiology, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom; 2Nephrology, Glasgow Royal Infirmary, Glasgow, Scotland, United Kingdom
NSF associates with the administration of gadolinium contrast in renal impairment. Of 481 patients who underwent renal CE-MRA 3 patients were identified as having NSF. 2 had AKI when imaged, third had deteriorating CKD (eGFR 16.1) and developed NSF three years later when on dialysis following further CE-MRA. All cases of gadodiamide-associated NSF from our unit (n=16) 13 were established on dialysis, 2 had AKI and one had eGFR of 8.3 ml/min. All patients developing NSF have AKI or stage 5 CKD, we found no NSF cases with an eGFR >15 ml/min.